Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC

Original Article

S. Lu, T. Kato, X. Dong, M.-J. Ahn, L.-V. Quang, N. Soparattanapaisarn, T. Inoue, C.-L. Wang, M. Huang, J.C.-H. Yang, M. Cobo, M. Özgüroğlu, I. Casarini, D.-V. Khiem, V. Sriuranpong, E. Cronemberger, T. Takahashi, Y. Runglodvatana, M. Chen, X. Huang, E. Grainger, D. Ghiorghiu, T.v.d. Gronde, and S.S. Ramalingam

N Engl J Med 2024;391:585-597

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
08/14/2024
Course expires: 
08/15/2026

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Please sign in or create an account to take the course.